Overall market sentiment has been neutral on Crispr Therapeutics AG (CRSP) stock lately. CRSP receives a Neutral rating from InvestorsObserver's Stock Sentiment Indicator.

Sentiment Score - ,neutral
Crispr Therapeutics AG has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CRSP!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.

Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.

InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.

For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CRSP Stock Today?

Crispr Therapeutics AG (CRSP) stock is trading at $149.33 as of 1:26 PM on Tuesday, Jul 6, a loss of -$6.55, or -4.2% from the previous closing price of $155.88. The stock has traded between $148.27 and $155.87 so far today. Volume today is low. So far 886,009 shares have traded compared to average volume of 1,370,649 shares.

To see InvestorsObserver's Sentiment Score for Crispr Therapeutics AG click here.

More About Crispr Therapeutics AG

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.



Source link